Report Ocean has published a new report on the Chemotherapy-Induced Peripheral Neuropathy Market in diverse regions to produce a report with more than 250+ pages.
The Global Chemotherapy-Induced Peripheral Neuropathy market held a market value of USD 967.73 Million in 2021 and is forecasted to reach USD 1,521.92 Million by the year 2030. The market is anticipated to register a CAGR of 5.16% over the projected period.
Request To Download Free Sample of This Strategic Report @ https://reportocean.com/industry-verticals/sample-request?report_id=ARS232
Chemotherapy Induced Peripheral Neuropathy (CIPN) is a side effect caused by antineoplastic agent. It is one of the most common side effects and a mostly sensory neuropathy which might be accompanied by motor and autonomic changes of varying duration and intensity. Increasing awareness coupled with the increasing emerging therapies are anticipated to boost the market growth.
Furthermore, increasing prevalence of cancer around the globe is also expected to fuel the market growth. Also, high prevalence of CIPN is also estimated to boost the market growth. The prevalence of CIPN varies by agent, with rates ranging from 19 % to more than 85%. Platinum-based medicines (70100 %), taxanes (1187 %), thalidomide and its analogues (2060 %), and ixabepilone (6065 %) have the highest reported rates.
Despite the driving factors, no standard assessment and current therapy limitations are expected to hinder the market growth during the forecast period. The overall impact of COVID-19 is neutral as the after effects of chemotherapy can be very severe and adoption of telehealth solutions made it possible for patients to consult their doctors and start their treatment.
Growth Influencers:
High prevalence of cancer around the globe
Prevalence of cancer is rising worldwide, which is also leading to rising cases of chemotherapy induced peripheral neuropathy. According to the National Cancer Institute, as of 2020, around 1,806,590 new cancer cases were estimated to be diagnosed in the United States. Moreover, as per the American Cancer Society, in 2021, about 1.9 million cancer cases were expected to be diagnosed and 608,570 people were expected to die in the United States. These growing number of cancer cases are leading to rising adoption of various treatment options for cancer. These treatment options include chemotherapy as well, which might lead to CIPN, hence boosting the market growth.
Download Free Sample of This Strategic Report with Industry Analysis @ https://reportocean.com/industry-verticals/sample-request?report_id=ARS232
Segments Overview:
The Global Chemotherapy-Induced Peripheral Neuropathy market is segmented based on therapy.
By Therapy,
Medications
Surgery
Transcutaneous Electrical Nerve Stimulation
Others
The medications segment is anticipated to witness the fastest growth rate of around 5.45% and also the largest market share of over 55% in 2021 owing to the growing preference of medications for CIPN treatment as compared to the other therapy options. The surgery segment is expected to surpass a market size of USD 150 million by 2025 owing to various technological advancements.
Regional Overview
Based on region, the Global Chemotherapy-Induced Peripheral Neuropathy market is divided into Europe, North America, Asia-Pacific, Middle East & Africa, and South America.
The North America region is expected to hold the largest market share of around 42%, amounting to around USD 2,834.8 million owing to the high prevalence of cancer in the region. Within the North American region, the U.S. accounted for a market size of USD 544.15 million in 2021 owing to the growing prevalence of CIPN.
The Asia Pacific region is anticipated to witness the fastest growth rate of around 5.7% owing to the growing R&D activities in the region and presence of various market players in the region. Within Asia Pacific, Japan witnessed a growth rate of around 6.47% over the projected period owing to the increasing prevalence of cancer.
Download Free Sample of This Strategic Report with Industry Analysis @ https://reportocean.com/industry-verticals/sample-request?report_id=ARS232
Europe region also witnessed significant growth owing to increasing awareness regarding CIPN. Within Europe, Germany accounted for a market size of USD 116.20 million and UK accounted for around USD 98.26 million in 2021. Germany witnessed the highest CIPN incident population of 165,095 cases, followed by the UK, with around 120,624 cases. Also, Spain witnessed a growth rate of around 5.75% over the forecast period, owing to the growing adoption of advanced technologies in the country. However, Spain witnessed the least the CIPN incident population of around 73,071 cases.
Competitive Landscape
Key players operating in the Global Chemotherapy-Induced Peripheral Neuropathy market include Orexo AB, MundiPharma International Ltd., Biodelivery Sciences International Inc., Hisamitsu Pharma Co., Teva Pharma Industries Ltd., CK life Science (WEX Pharma), Daiichi Sankyo Co., Pfizer Inc., and Roche Holding AG, among others. The cumulative market share of the four major players is close to 35%.
These market players are involved in collaborations, mergers & acquisitions, and new product launches to strengthen their market presence. For instance, in December 2021, Hisamitsu Pharmaceutical Co., Inc. signed a licensing agreement with RaQualia Pharma Inc. for the latters novel sodium channel blocker. The drug is used for the treatment of chronic pain.
To Get More Business Strategies For Request Free Sample Report @ https://reportocean.com/industry-verticals/sample-request?report_id=ARS232
Table of Content:
- Report Overview
- Global Growth Trends
- Competition Landscape by Key Players
- Data Segments
- North America Market Analysis
- Europe Market Analysis
- Asia-Pacific Market Analysis
- Latin America Market Analysis
- Middle East & Africa Market Analysis
- Key Players Profiles Market Analysis
- Analysts Viewpoints/Conclusions
- Appendix
Continue……..
The Global Chemotherapy-Induced Peripheral Neuropathy market report provides insights on the below pointers:
Market Penetration: Provides comprehensive information on the market offered by the prominent players
Market Development: The report offers detailed information about lucrative emerging markets and analyzes penetration across mature segments of the markets
Market Diversification: Provides in-depth information about untapped geographies, recent developments, and investments
Competitive Landscape Assessment: Mergers & acquisitions, certifications, product launches in the Global Chemotherapy-Induced Peripheral Neuropathy market have been provided in this research report. In addition, the report also emphasizes the SWOT analysis of the leading players.
Product Development & Innovation: The report provides intelligent insights on future technologies, R&D activities, and breakthrough product developments
7MM Prevalent Population of CIPN; Disease Background and Overview- Sign & Symptoms, Pathophysiology, Risk Factors, Diagnosis
For Further Information Regarding this Report: Request a Free Sample @ https://reportocean.com/industry-verticals/sample-request?report_id=ARS232
Competitive Intelligence Analysis for CIPN
Country Wise Epidemiology of Cancer Pain: United States Epidemiology- Prevalence Cases of CIPN in the U.S., Gender Specific CIPN Prevalence, Age-Specific CIPN Prevalence; EU5 Epidemiology (Germany, France, Italy, Spain, & the UK); Japan Epidemiology
Current Treatment Practices: Clinical Practice Guideline-Treatment of CIPN; Patient Journey
Marketed Drugs: Olesoxime (TRO19622)-MedImmune/Abbott Laboratories Inc.-Product Description, Regulatory Milestones, Developmental Activities, Pivotal Clinical Trials; Calmangafodipir-Egetis Therapeutics/Solasia Pharma K.K.; Pregabalin-Pfizers
Emerging Drugs: Tetrodotoxin (TTX)-Wex Pharmaceuticals-Product Description, Clinical Development, Clinical Trials Information, Safety & Efficacy, Product Profile; Thrombomodulin alfa-Veloxis Pharmaceuticals; Sodium Selenite Pentahydrate-Boryung Pharmaceutical Co., Ltd; Memantine-Mendel AI; Nicotinamide Riboside-ChromaDex, Inc.
The Global Chemotherapy-Induced Peripheral Neuropathy market report answers questions such as:
What is the market size and forecast of the Global Chemotherapy-Induced Peripheral Neuropathy Market?
What are the inhibiting factors and impact of COVID-19 on the Global Chemotherapy-Induced Peripheral Neuropathy Market during the assessment period?
Which are the products/segments/applications/areas to invest in over the assessment period in the Global Chemotherapy-Induced Peripheral Neuropathy Market?
What is the competitive strategic window for opportunities in the Global Chemotherapy-Induced Peripheral Neuropathy Market?
What are the technology trends and regulatory frameworks in the Global Chemotherapy-Induced Peripheral Neuropathy Market?
What is the market share of the leading players in the Global Chemotherapy-Induced Peripheral Neuropathy Market?
What modes and strategic moves are considered favorable for entering the Global Chemotherapy-Induced Peripheral Neuropathy Market?
Key Metrics Explored in Report Ocean Research Service:
Market Size: Quantifying the total value or volume of the market to provide a comprehensive understanding of its scale and potential.
Market Growth Rate: Measuring the rate at which the market is growing over specific periods to assess attractiveness and potential for investment.
Market Share: Analyzing the portion or percentage of the market captured by specific companies or products, providing insights into competitive positions.
Customer Satisfaction: Assessing levels of satisfaction or dissatisfaction among customers with a focus on products, services, or brands. This aids in gauging customer loyalty and identifying areas for improvement.
Pricing Analysis: Examining pricing strategies, including average prices, price differentials, and price elasticity, to understand market dynamics.
Market Segmentation: Dividing the market into distinct segments based on demographics, geography, behavior, or psychographics to understand varying needs and preferences.
Customer Acquisition Cost (CAC): Calculating the cost of acquiring a new customer to evaluate the efficiency of marketing and sales efforts.
Customer Lifetime Value (CLV): Measuring the total value a customer generates over their entire relationship with a company to assess long-term profitability.
Return on Investment (ROI): Evaluating the profitability and effectiveness of investments or marketing campaigns by measuring returns relative to costs.
Competitive Analysis: Assessing the performance and strategies of competitors, including market share, revenue growth, product portfolio, and customer satisfaction.
Key Performance Indicators (KPIs): Utilizing specific metrics to measure business or organizational performance, such as sales growth, market penetration, customer retention rate, and profitability.
Request full Report: @ https://reportocean.com/industry-verticals/sample-request?report_id=ARS232
About Report Ocean:
Report Ocean stands as a preeminent provider of market research reports within the industry. Renowned globally, we are acclaimed for delivering insightful and informative research reports. Our commitment lies in furnishing clients with a comprehensive blend of both quantitative and qualitative research outcomes. As an integral component of our expansive global network and thorough industry coverage, we offer an in-depth reservoir of knowledge that empowers strategic and well-informed business decisions. Our approach integrates cutting-edge technology, advanced analysis tools, and our proprietary research models, all underpinned by years of expertise. This synergy allows us to craft essential details and facts that consistently surpass expectations.
Connect with Us:
Report Ocean:
Address: 500 N Michigan Ave, Suite 600, Chicago, Illinois 60611 – UNITED STATES
Visit Our News Website: https://reportocean.com
Tel: +1888 212 3539 (US – TOLL FREE)
Email: [email protected]